# Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

> **NCT04803201** · PHASE2 · SUSPENDED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 170 (estimated)

## Conditions studied

- Angioimmunoblastic T-cell Lymphoma
- Enteropathy-Associated T-Cell Lymphoma
- Follicular T-Cell Lymphoma
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
- Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
- Peripheral T-Cell Lymphoma, Not Otherwise Specified

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Etoposide
- **DRUG:** Duvelisib
- **DRUG:** Oral azacitidine

## Key facts

- **NCT ID:** NCT04803201
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-10-08
- **Primary completion:** 2027-05-19
- **Final completion:** 2027-05-19
- **Target enrollment:** 170 (ESTIMATED)
- **Why stopped:** Interim Analysis
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04803201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04803201, "Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04803201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*